Stephan Winnik

TL;DR: There is translational evidence for a role of sirtuins in patients with endothelial dysfunction, type 1 or type 2 diabetes and longevity, and it is anticipated that this field will move quickly from bench to bedside.

TL;DR: Using HDL from children and adults with chronic kidney dysfunction (HDL(CKD), a population with high cardiovascular risk, it is demonstrated that HDL in contrast to HDL(Healthy) promoted endothelial superoxide production, substantially reduced nitric oxide bioavailability, and subsequently increased arterial blood pressure (ABP).

TL;DR: Exogenous SIRT1 diminishes endothelial activation in ApoE-/- mice, but does not affect endothelium-dependent vasodilatation, and treatment with lipopolysaccharide to boost NF-κB signaling led to a more pronounced endothelial expression.

TL;DR: Obesity-induced endothelial dysfunction depends on the ‘endothelial’ MR and is mediated by an imbalance of oxidative stress-modulating mechanisms, therefore, MR antagonists may represent an attractive therapeutic strategy in the increasing population of obese patients to decrease vascular dysfunction and subsequent atherosclerotic complications.

TL;DR: Reduction in Pcsk9 secretion is identified as a novel effect of Sirt1 activity and Ldlr is uncovered as a prerequisite for Sirt 1-mediated atheroprotection in mice.